Vaccine Partnering Terms and Agreements

The Vaccine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

• Trends in vaccine and adjuvant partnering deals
• Deal terms analysis
• Partnering agreement structure
• Partnering contract documents
• Top deals by value
• Most active dealmakers
• Average deal terms for vaccines

The report provides a detailed understanding and analysis of how and why companies enter vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 1,500 links to online copies of actual vaccine deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of vaccine dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in vaccine dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading vaccine deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of vaccine deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of vaccine partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in vaccine partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of vaccine technologies and products.

Vaccine Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to vaccine trends and structure of deals entered into by leading companies worldwide.

Vaccine Partnering Terms and Agreements includes:

• Trends in vaccine dealmaking in the biopharma industry since 2007
• Analysis of vaccine deal structure
• Access to headline, upfront, milestone and royalty data
• Case studies of real-life vaccine deals
• Access to over 1,500 vaccine deal documents
• The leading vaccine deals by value since 2007
• Most active vaccine dealmakers since 2007
• The leading vaccine partnering resources

In Vaccine Partnering Terms and Agreements, the available contracts are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy target

Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Vaccine Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1,500 vaccine deals. Analyzing actual contract agreements allows assessment of the following:

• What are the precise vaccine rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Vaccine Partnering Terms and Agreements provides the reader with the following key benefits:

• In-depth understanding of vaccine and adjuvant deal trends since 2007
• Access to headline, upfront, milestone and royalty data
• Analysis of the structure of vaccine agreements with numerous real life case studies
• Comprehensive access to over 1500 actual vaccine contracts entered into by the world’s biopharma companies
• Detailed access to actual vaccine contracts enter into by the leading fifty bigpharma companies
• Insight into the terms included in a vaccine agreement, together with real world clause examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of contents

Executive Summary

Chapter 1 – Introduction        

Chapter 2 – Trends in vaccine dealmaking
2.1. Introduction          
2.2. Vaccine partnering over the years 
2.3. Bigpharma vaccine dealmaking activity     
2.4. Bigpharma not active in vaccine partnering
2.5. Vaccine partnering by deal type    
2.6. Vaccine partnering by disease type
2.7. Average deal terms for vaccine partnering
2.7.1 Vaccine partnering headline values         
2.7.2 Vaccine deal upfront payments
2.7.3 Vaccine deal milestone payments
2.7.4 Vaccine royalty rates      

Chapter 3 – Leading vaccine deals     
3.1. Introduction          
3.2. Top vaccine deals by value
3.3. Top vaccine deals involving bigpharma

Chapter 4 – Bigpharma vaccine deals
4.1. Introduction          
4.2. How to use bigpharma vaccine partnering deals    
4.3. Bigpharma vaccine partnering company profiles    
Abbott
Astellas          
AstraZeneca   
Baxter International     
Bayer 
Biogen Idec    
Boehringer Ingelheim  
Bristol-Myers Squibb  
CSL    
Daiichi Sankyo
Gilead Sciences          
GlaxoSmithKline         
Kyowa Hakko Kirin      
Merck & Co    
Merck KGaA   
Mitsubishi Tanabe       
Novartis         
Pfizer 
Roche
Sanofi 
Takeda

Chapter 5 – Vaccine dealmaking directory
5.1. Introduction          
5.2. Company A-Z       
5.3. By stage of development  
Discovery       
Formulation    
Marketed        
Phase I
Phase II          
Phase III         
Preclinical      
Regulatory      
5.4. By deal type         
Asset purchase
Co-development          
Collaborative R&D      
Contract service         
Co-promotion  
CRADA
Development  
Distribution     
Equity purchase          
Grant  
Joint venture   
Licensing        
Litigation        
Manufacturing 
Marketing       
Material transfer         
Option
Research        
Settlement      
Spin out          
Supply
Technology
Termination    
Warranty        
5.5. By therapy area    
Immunology    
Infectives       
Inflammatory
Respiratory     
5.6. By vaccine technology type          

Chapter 6 – Vaccine partnering resource center        
6.1. Online vaccine partnering 
6.2. Vaccine partnering events
6.3. Further reading on vaccine dealmaking     
About Wildwood Ventures        
Current Partnering      
Current Agreements    
Current Reports          
Recent titles from CurrentPartnering    
Order Form – Reports 

Appendices        
Appendix 1 –Vaccine dealmaking – by company A-Z    
Appendix 2 – Vaccine dealmaking – by deal type
Appendix 3 – Vaccine dealmaking – by stage of development
Appendix 4 –  Vaccine dealmaking – by therapy area
Appendix 5 – Deal type definitions
Appendix 6 – Example vaccine partnering agreement

List of Figures

Figure 1: Vaccine partnering since 2007          
Figure 2: Bigpharma – top 50 – vaccine deals 2007 to 2012      
Figure 3: Bigpharma vaccine deal frequency – 2007 to 2012     
Figure 4: Inactive bigpharma in vaccine partnering 2007-2012  
Figure 5: Vaccine partnering by deal type since 2007   
Figure 6: Vaccine partnering by disease type since 2007          
Figure 7: Vaccine partnering by infectives target since 2007    
Figure 8: Vaccine partnering by oncology target since 2007     
Figure 9: Vaccine deals with a headline value – by stage of development          
Figure 10: Vaccine deal headline value distribution, US$million – discovery stage         
Figure 11: Vaccine deal headline value distribution, US$million – preclinic stage
Figure 12: Vaccine deal headline value distribution, US$million – phase I stage 
Figure 13: Vaccine deal headline value distribution, US$million – phase II stage
Figure 14: Vaccine deal headline value distribution, US$million – phase III stage
Figure 15: Vaccine deal headline value distribution, US$million – marketed stage          
Figure 16: Vaccine deal headline value – median value by stage of development
Figure 17: Vaccine deals with upfront payment values – by stage of development         
Figure 18: Vaccine deal upfront payment distribution, US$million – discovery stage deals         
Figure 19: Vaccine deal upfront payment distribution, US$million – prelinic stage deals 
Figure 20: Vaccine deal upfront payment distribution, US$million – phase I stage deals 
Figure 21: Vaccine deal upfront payment distribution, US$million – phase II stage deals
Figure 22: Vaccine deal upfront payment distribution, US$million – phase III stage deals
Figure 23: Vaccine deal upfront payment distribution, US$million – marketed stage deals          
Figure 24: Vaccine deal upfront value – median value by stage of development 
Figure 25: Vaccine deals with milestone payment – by stage of development    
Figure 26: Vaccine deal milestone payment distribution, US$million – discovery stage deals     
Figure 27: Vaccine deal milestone payment distribution, US$million – prelinic stage deals         
Figure 28: Vaccine deal milestone payment distribution, US$million – phase I stage deals         
Figure 29: Vaccine deal milestone payment distribution, US$million – phase II stage deals        
Figure 30: Vaccine deal milestone payment distribution, US$million – phase III stage deals       
Figure 31: Vaccine deal milestone payment distribution, US$million – marketed stage deals      
Figure 33: Vaccine deals with royalty rates      
Figure 34: Top vaccine deals by value since 2007        
Figure 34: Top vaccine deals signed by bigpharma value since 2007    
Figure 35: Online partnering resources
Figure 36: Forthcoming partnering events